NCT04509726View on ClinicalTrials.gov

EBV Specific Cytokine Secreting TCR-T Cells in the Treatment of EBV-Positive Metastatic/Refractory Nasopharyngeal Carcinoma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

EBV-specific TCR-T cell with cytokine auto-secreting element

Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with cytokine auto-secreting element

Trial Locations (1)

400037

RECRUITING

Department of Oncology, Xinqiao Hospital, Chongqing

All Listed Sponsors
collaborator

TCRCure Biopharma Ltd.

INDUSTRY

lead

Xinqiao Hospital of Chongqing

OTHER